The medication is commonly used to help with localized symptomatic support for conditions involving inflammatory or irritative states and damaged surface tissues. Its use is commonly applied across gynecological, proctological, and dermatological domains where specific surface actions are used for managing symptoms.

Relief for Localized Lesions and Inflammation

This medication is commonly used to manage symptoms related to inflammatory or irritative states such as vaginitis and cervicitis (inflammation of the vagina and cervix), as well as cervical erosions (ectopia). The medication is relevant for easing symptoms that arise from anal fissures, external hemorrhoids, mouth ulcers, or skin ulcers. By addressing symptoms related to inflammatory or irritative states and providing support for tissue repair, it contributes to easing distress during symptomatic periods.

“This agent plays a role in managing symptoms by supporting cleansing and regeneration in areas affected by inflammation and superficial damage.”

Support for Tissue Cleansing and Bleeding Control

This medication is relevant in situations where localized tissue damage is present, assists with cleansing, and may help patients cope more steadily with symptom fluctuations related to tissue stress. A key benefit may be its role in managing minor surface bleeding from fragile tissues, contributing to easing the overall symptom load. This supportive role is applied in clinical settings that involve acute or unstable symptom patterns, such as managing pressure sores caused by devices.

---

Quick Fact: Relief for Tissue Damage and Bleeding

The medication is commonly used to help with localized surface lesions and is relevant for easing symptoms that interfere with daily comfort, particularly in situations involving minor surface bleeding and a need for tissue support.

Who Can and Cannot Use Ваготил?

This section outlines the official population eligibility and non-eligibility rules for Ваготил (Policresulen), based strictly on authoritative government regulatory documents.

Classification	Population/Condition
Contraindicated	Known hypersensitivity or allergy to Policresulen or any excipients.
Not Indicated	Children and adolescents under 18 years, due to lack of established clinical experience.
Not Indicated	Postmenopausal women (for the vaginal suppository form), due to insufficient data.
Conditional Use	Pregnancy: Use only when strictly indicated, especially avoided in the third trimester.
Conditional Use	Lactation: Use only after considering potential risks, as excretion into breast milk is not known.
Prohibited Use	During menstruation and while having sexual intercourse [during and immediately after treatment].

Eligibility is firmly established for adults for the approved local indications. Regulatory information does not typically impose restrictions based on systemic comorbidities, such as hepatic or renal impairment, due to the drug's localized action and minimal systemic absorption. Use in any patient population outside of the established adult indication is officially deemed either not indicated or requires conditional use as defined in the official product labeling.

Interactions with other medicines and products

The official interaction profile for Ваготил (Policresulen) is strictly defined by its pharmacological classification as a localized topical agent. Due to the regulatory determination of minimal systemic absorption, the official labeling documents state that no systemic pharmacokinetic interactions are documented, meaning there are no officially listed interactions involving CYP enzymes or drug transporters.

The documented constraints are limited exclusively to local administration requirements at the site of application.

Interaction Category	Official Regulatory Restriction
Local Co-Administration	Simultaneous use of other medicines for use in the vagina is formally restricted.
Substance Interference	The use of irritating soap or products that could interfere with the local action must be avoided during treatment.

The most significant interaction constraint is based on a timing-based rule against co-administration. Regulatory documents state that Policresulen co-administration with other local agents at the same site and at the same time must be avoided. This is classified as a local formal restriction because the possibility of a pharmacodynamic or chemical interaction cannot be excluded at the application site. This specific, limited interaction profile confirms the product's non-systemic drug delivery structure as recognized by regulatory authorities.

Pharmacodynamic Mechanism of Policresulen

The action of Ваготил (Policresulen) is a highly localized chemical process defined by three core pharmacodynamic functions that prepare the affected tissue surface. This mechanism is non-systemic.

Selective Coagulation and Tissue Sloughing

Policresulen's high acidity causes immediate and irreversible denaturation and precipitation of proteins exclusively in pathologically altered or necrotic tissue. This chemical interaction facilitates the sloughing off of the damaged material, exposing the underlying viable tissue. This action establishes a physiological prerequisite for the re-epithelialization cascade.

Local Hemostasis and Vascular Contraction

The mechanism also manages minor surface bleeding through a dual effect: the immediate precipitation of blood proteins forms a physical seal, and a localized, non-neurogenic vasoconstriction of superficial capillaries occurs. This maintains local vascular integrity, preventing further localized disruption during the subsequent tissue repair sequence.

Antimicrobial Activity Mediated by Low pH

This function provides a broad-spectrum antiseptic effect by creating an immediate, highly acidic microenvironment. The low pH disrupts the cell membranes and metabolic enzymes of most pathogens. The mechanism causes a reduction in local microbial viability, establishing a clean local environment that supports the initiation of the repair cycle.

How Ваготил is Used: Administration Guidelines

The usage of Policresulen (Ваготил) is strictly confined to localized, non-systemic application, with specific administration protocols defined by its two primary forms: the vaginal suppository and the topical solution concentrate. The application typically follows guidelines regarding the appropriate route, frequency, and duration of use.

Administration Routes and Standard Dosing

Dosage Form	Route of Administration	Standard Adult Regimen	Frequency Pattern
Vaginal Suppository (90 mg)	Vaginal	Insert one suppository.	Once every two days (intermittent use).
Topical Solution (Concentrate)	Buccal/Oral Mucosa	Rinse with half a capful.	Up to four times daily.

Contextual Use and Duration

The suppository is preferably inserted deep into the vagina in the evening before going to sleep to prevent premature expulsion, and it may be moistened with water briefly to facilitate insertion. For oral mucosal use, the solution must be held for at least one minute, then spit out. A sanitary pad should be used during vaginal treatment to prevent soiling of clothing.

Treatment duration is typically limited: the course for the vaginal suppository should generally not exceed 9 days. Furthermore, treatment must be interrupted during the menstrual cycle. The suppository form is generally not indicated for use in adolescents under 18 years.

Research evidence / Overview of Studies for Ваготил (Policresulen)

The research available for Policresulen, the active ingredient in Ваготил, consists of various types of clinical studies, ranging from randomized trials to observational data and large case series. The evidence base focuses on how the medicine was studied for localized conditions where researchers examined outcomes related to physical processes like tissue sloughing and epithelialization. Findings describe group patterns observed in the studies but do not determine whether an individual will experience similar observed changes.

---

Evidence for Gynecological Conditions: Vaginitis and Cervical Tissue

Clinical trials and controlled studies have been used in research exploring how symptoms change over time for adult women diagnosed with various inflammatory or irritative states of the vagina and cervix, such as vaginitis and cervicitis and cervical ectopia.

Researchers have applied the medicine in studies examining patient-reported experiences related to outcomes linked to inflammatory or irritative states such as vaginal discharge, local discomfort, and pain. In these gynecological trials, studies monitored several endpoints, including clinical assessments of symptoms and, in some cases, specific microbiological results. Findings describe patterns observed in the studies related to changes in reported symptoms and local tissue characteristics during the study period.

For conditions involving changes to the cervical tissue, studies primarily focused on visual and physical assessments to track the process of epithelialization and the coagulation of pathologically altered tissue. The research highlights changes measured during the study period, such as reported patterns related to the observation of less surface bleeding and the progression of epithelialization across the affected area.

---

Research Gaps and Remaining Uncertainties

Synthesizing the research across all indications highlights several documented limitations and areas where certainty remains low. The long-term effects are not fully established across the indications studied because follow-up durations were limited in many core trials.

Furthermore, the existing evidence consists of different types of studies, with some data sets derived from older, non-blinded clinical observations alongside contemporary systematic reviews or meta-analyses. For many conditions, comparative evidence is lacking against the full spectrum of modern, evidence-based therapies. Finally, the results apply only to the populations studied, meaning research provides context but does not determine whether an individual will experience similar observed changes.

Key Studies & References

1. Policresulen Vaginal Suppository Product Labeling (DailyMed/National Library of Medicine)
2. Vaginitis - Clinical Overview and Standard Treatments (Used for disease context and comparative research gaps)

Common questions about Ваготил (FAQ)

Q: Does Ваготил (Vagothyl) cure bacterial vaginosis or is it only for trichomonas?

A: Official product information states that Ваготил is indicated for use in treating various vaginal discharges, including those associated with infections from bacterial flora and from trichomonas. The drug is also approved for conditions such as cervicitis and erosion of the portio vaginalis.

Q: Can I use Ваготил during menstruation?

A: Regulatory documents indicate that treatment with Ваготил is typically interrupted during the menstrual period. Treatment is usually resumed once menstruation has ended, as directed by the prescribing professional.

Q: What is the recommended duration of treatment with Ваготил?

This question is too close to core section content.

Q: How long does it take for Ваготил to work?

A: Official product information does not specify an exact timeframe for when the effects of Ваготил will begin to be noticeable. The focus is on completing the full prescribed treatment duration, which may vary depending on the patient's condition.

Q: What should I do if I miss a dose of Ваготил?

A: The official product information states that a missed dose of Ваготил should not be compensated by doubling the next dose. The recommended course of treatment should continue as originally scheduled.

Q: Is Ваготил safe to use with condoms or diaphragms?

A: Regulatory documents state that sexual intercourse is advised against during the course of treatment with Ваготил. The product information does not explicitly detail the drug's effects on the integrity or effectiveness of barrier contraceptives like condoms or diaphragms.

Q: Are there any food or drink restrictions while using Ваготил?

A: Regulatory documents state that there are no specific food or drink restrictions required while using Ваготил. The drug is a topical application, and the primary considerations are related to local use and treatment effectiveness.

Q: Can Ваготил cause dryness or irritation?

A: Official product information notes that Ваготил may occasionally cause local irritation at the application site. This may present as a mild stinging or burning sensation, and is generally considered transient and temporary.

Q: Can Ваготил be used for infections outside of the vagina, like a skin infection or a throat infection?

A: Regulatory documents state that Ваготил is specifically indicated for vaginal and cervical pathology. These conditions include various forms of vaginitis and cervical erosions, and it is not approved for infections or use outside of this local area.

How to Store and Dispose of Vagothyl (Policresulen)

Storage and disposal of Vagothyl must strictly follow conditions mandated by regulatory labeling to maintain stability and manage environmental risks.

Storage Requirements

Condition	Regulatory Stipulation
Temperature	Store in a cool, well-ventilated area; some forms require temperature below 25 C.
Protection	Keep protected away from direct sunlight, moisture, and light.
Container	Container must be kept tightly closed and in a properly labeled container.
Safety	Keep out of the sight and reach of children; avoid storage near strong oxidizers or many metals.

Disposal Instructions

Unused product must not be used after the expiry date. Contents and containers must be disposed of in accordance with local and national regulations. To protect the environment, the product must not be discharged to sewer systems, drains, water courses, or the soil.